PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of ijpsychHomeCurrent issueInstructionsSubmit article
 
Indian J Psychiatry. 2000 Jan-Mar; 42(1): 52–56.
PMCID: PMC2957003

COMPARATIVE STUDY OF RISPERIDONE AND HALOPERIDOL ON CLINICAL AND PSYCHOSOCIAL PARAMETERS IN TREATMENT OF SCHIZOPHRENIA : A RANDOMISED OPEN TRIAL

Abstract

The study compares the efficacy of risperidone and haloperidol in patients of schizophrenia on various clinical and psychosocial parameters.

In the present open, comparative study, in patients suffering from schizophrenia (DSM-IV), 50 patients each were randomly treated with risperidone and haloperidol over a period of 1 year. The clinical improvement was judged on PANSS (Positive and Negative Symptom Scale) and CGIS (Clinical Global Impression Scale). The improvement in psychosocial functioning and other areas was judged using a five point scale (0-4). Though the improvement on PANSS was comparable in both the groups except on the general psychopathology subscale, on CGIS a better improvement profile was observed in risperidone group. In the other psychosocial areas such as social functioning, productivity and education a significantly more number of patients showed improvement in risperidone group as compared to haloperidol group. In significantly less number of patients suicidality and rehospitalization was found in risperidone group as compared to haloperidol group.

Keywords: Risperidone, haloperidol, social integration, quality of life

Full Text

The Full Text of this article is available as a PDF (201K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Bech P, Angst J. Quality of life in anxiety and social phobia. Int Clin Psychopharmacol. 1996 Jun;11 (Suppl 3):97–100. [PubMed]
  • Carman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol. 1995 Nov;10(4):207–213. [PubMed]
  • Cesková E, Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry. 1993 Jul;26(4):121–124. [PubMed]
  • Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993 Feb;13(1):25–40. [PubMed]
  • Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J, Heylen S. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand. 1992 Apr;85(4):295–305. [PubMed]
  • Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. [PubMed]
  • Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994 Jun;151(6):825–835. [PubMed]

Articles from Indian Journal of Psychiatry are provided here courtesy of Medknow Publications